Hoffman ALS Clinical Trial Awards Program

Ends on 26 November 2024

The Hoffman ALS Clinical Trial Awards Program helps develop new and improved ALS therapies by supporting early-stage clinical trials. These trials generally produce data on safety, dosing, and biomarkers that are essential for moving an investigational therapy one step closer to being evaluated by the FDA.

More details: https://www.als.org/